MEN.L

Molecular Energies
Molecular Energies - Last Day of Dealing on AIM
26th April 2024, 06:00
TwitterFacebookLinkedIn
To continue viewing RNS, please confirm that you are a Private Investor*

* A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:

  1. Obtains access to the information in a personal capacity;
  2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
  3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
  4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
  5. Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
  6. Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
RNS Number : 1174M
Molecular Energies PLC
26 April 2024
 

26 April 2024

 

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU NO. 596/2014) AS IT FORMS PART OF UK DOMESTIC LAW BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018 (AS AMENDED) ("MAR"). UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INSIDE INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN.

 

MOLECULAR ENERGIES PLC

("Molecular" or the "Company")

 

Last Day of Dealings on AIM

Post Cancellation Shareholder Communications

 

Molecular Energies plc (AIM: MEN), provides an update on the matters described in the circular to shareholders dated 28 March 2024 and further information on shareholder communication following cancellation of the admission of the Company's ordinary shares to trading on AIM ("Cancellation").

Cancellation of admission to AIM

Cancellation will take place at 7.00 a.m. on 29 April 2024. The final day of dealings in the Company's shares on AIM is today, 26 April 2024.

Website

The current format of the website of the Company will be re-structured and will be live with effect from 1 May 2024.

The website will provide up to date information with regard to all material developments of the Company and members of its group. Whilst some sections of the current website will no longer be applicable, in order to promote transparency as a private company new features will be added with the aim of strengthening the connection between the Company and its remaining shareholders.

Communication

Molecular recognises that as a private company, it is imperative to ensure that those who came on its journey are kept regularly informed.

Accordingly, Molecular will publish news of all material developments both on its website and via its social media accounts, which it will continue to maintain. A regular newsletter providing business updates will be issued with the first anticipated by 30 September 2024, by which date the Company anticipates that it will publish its annual accounts for the year ended 31 December 2023. The Company will maintain its shareholder communications email address - info@molecularenergiesplc.com - and investors wishing to receive these regular updates or enter into dialogue with the Company are encouraged to email that address requesting to sign up.

Dealing Arrangements

The Company's ordinary shares will be admitted to trading on the JP Jenkins securities matching platform from the 29 April 2024. 

JP Jenkins provides a securities matching venue for unlisted or unquoted assets in companies, enabling shareholders and prospective investors to buy and sell shares on a matched bargain basis. JP Jenkins is a trading name of InfinitX Limited and Appointed Representative of Prosper Capital LLP (FRN453007).

Shareholders wishing to trade these securities can do so through their stockbroker. Trades will be conducted at a level that JP Jenkins is able to match a willing seller and a willing buyer. Trades can be conducted, and limits can be accepted, during normal business hours. Shareholders or potential investors can place limits via their existing UK regulated stockbroker.

The indicative pricing for the ordinary Shares (ISIN: GB00BMT80K89), as well as the transaction history, will be available on the JP Jenkins website at (https://jpjenkins.com/company/molecular-energies/).

The provision of the matched bargain facility will be kept under review by the Board and, in determining whether to continue to offer a matched bargain facility, the Company shall consider expected (and communicated) shareholder demand for such a facility as well as the composition of the Company's register of members and the costs to the Company and shareholders.

 

 Molecular Energies PLC

Peter Levine, Chairman

Rob Shepherd, Group FD

+44 (0)20 7016 7950

info@molecularenergiesplc.com

Cavendish Capital Markets Limited (Nominated Adviser & Broker)

Simon Hicks

George Dollemore

+44 (0)20 7220 0500

Tavistock (Financial PR & IR)

Simon Hudson, Nick Elwes, Saskia Sizen

+44 (0)20 7920 3150

JP Jenkins (Matched Bargain Settlement Facility)

Veronika Oswald - Director

+44 (0)20 7469 0937

 

For the purposes of MAR, Article 2 of Commission Implementing Regulation (EU) 2016/1055 and the UK version of such implementing regulation (as amended), the person responsible for arranging for the release of this Announcement on behalf of the Company is Peter Levine, Chairman.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCFLFVTSSIEFIS]]>
TwitterFacebookLinkedIn